<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/340288BD-BCA1-46AA-BA5C-D85DDA0D29C8"><gtr:id>340288BD-BCA1-46AA-BA5C-D85DDA0D29C8</gtr:id><gtr:name>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/97DAD014-E63E-4AAA-84F7-98EAD3B32BDB"><gtr:id>97DAD014-E63E-4AAA-84F7-98EAD3B32BDB</gtr:id><gtr:name>Moscow Regional AIDS Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39B73BF0-6F1A-4F02-9639-60736B28A074"><gtr:id>39B73BF0-6F1A-4F02-9639-60736B28A074</gtr:id><gtr:name>Nye Pluss</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D49A6E9-BF40-4299-915A-1E204BF44D5D"><gtr:id>1D49A6E9-BF40-4299-915A-1E204BF44D5D</gtr:id><gtr:name>Portuguese Group of Activists Treatments for HIV/AIDS Pedro Santos (GAT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E"><gtr:id>D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E</gtr:id><gtr:name>City, University of London</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A32E0CF1-72B8-47D2-A614-D74456F65DFD"><gtr:id>A32E0CF1-72B8-47D2-A614-D74456F65DFD</gtr:id><gtr:name>Positive Voices</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2B4890EC-5704-4F99-AE13-CC1371378CBB"><gtr:id>2B4890EC-5704-4F99-AE13-CC1371378CBB</gtr:id><gtr:name>Copenhagen University Hospital</gtr:name><gtr:address><gtr:line1>Kettegaard Alle 30</gtr:line1><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A2A453F-81B2-4B90-B942-A83268D4F47F"><gtr:id>0A2A453F-81B2-4B90-B942-A83268D4F47F</gtr:id><gtr:name>CheckpointLX</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB"><gtr:id>F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB</gtr:id><gtr:name>University of Paris Diderot (Paris 7)</gtr:name><gtr:address><gtr:line1>6th European PCRD</gtr:line1><gtr:line2>13 rue Pierre et Marie Curie</gtr:line2><gtr:postCode>F-75205</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/121A1351-0BDF-4049-996D-13B5E3937333"><gtr:id>121A1351-0BDF-4049-996D-13B5E3937333</gtr:id><gtr:name>San Paolo Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B692BCF2-0F6F-47F4-9CD9-AB35179CD985"><gtr:id>B692BCF2-0F6F-47F4-9CD9-AB35179CD985</gtr:id><gtr:name>St. James's Hospital, Dublin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421AD70F-9A6E-48CE-9C42-6C508F1FBAD8"><gtr:id>421AD70F-9A6E-48CE-9C42-6C508F1FBAD8</gtr:id><gtr:name>Eastern Virginia Medical School (EVMS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/476C28D0-C84A-426C-AA10-48C0CCE16B06"><gtr:id>476C28D0-C84A-426C-AA10-48C0CCE16B06</gtr:id><gtr:name>National Institute for Infectious Diseas</gtr:name><gtr:address><gtr:line1>National Inst. for Infectious Diseases</gtr:line1><gtr:line2>Department of Bacterial Science</gtr:line2><gtr:line3>Shinjuku Ku, Toyama 1 - 23 - 1</gtr:line3><gtr:postCode>162840</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55AD066E-3431-4A59-AB02-D6FFA3D1DC84"><gtr:id>55AD066E-3431-4A59-AB02-D6FFA3D1DC84</gtr:id><gtr:name>GGD Amsterdam</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/340288BD-BCA1-46AA-BA5C-D85DDA0D29C8"><gtr:id>340288BD-BCA1-46AA-BA5C-D85DDA0D29C8</gtr:id><gtr:name>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39B73BF0-6F1A-4F02-9639-60736B28A074"><gtr:id>39B73BF0-6F1A-4F02-9639-60736B28A074</gtr:id><gtr:name>Nye Pluss</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D49A6E9-BF40-4299-915A-1E204BF44D5D"><gtr:id>1D49A6E9-BF40-4299-915A-1E204BF44D5D</gtr:id><gtr:name>Portuguese Group of Activists Treatments for HIV/AIDS Pedro Santos (GAT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/121A1351-0BDF-4049-996D-13B5E3937333"><gtr:id>121A1351-0BDF-4049-996D-13B5E3937333</gtr:id><gtr:name>San Paolo Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B692BCF2-0F6F-47F4-9CD9-AB35179CD985"><gtr:id>B692BCF2-0F6F-47F4-9CD9-AB35179CD985</gtr:id><gtr:name>St. James's Hospital, Dublin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/476C28D0-C84A-426C-AA10-48C0CCE16B06"><gtr:id>476C28D0-C84A-426C-AA10-48C0CCE16B06</gtr:id><gtr:name>National Institute for Infectious Diseas</gtr:name><gtr:address><gtr:line1>National Inst. for Infectious Diseases</gtr:line1><gtr:line2>Department of Bacterial Science</gtr:line2><gtr:line3>Shinjuku Ku, Toyama 1 - 23 - 1</gtr:line3><gtr:postCode>162840</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55AD066E-3431-4A59-AB02-D6FFA3D1DC84"><gtr:id>55AD066E-3431-4A59-AB02-D6FFA3D1DC84</gtr:id><gtr:name>GGD Amsterdam</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/97DAD014-E63E-4AAA-84F7-98EAD3B32BDB"><gtr:id>97DAD014-E63E-4AAA-84F7-98EAD3B32BDB</gtr:id><gtr:name>Moscow Regional AIDS Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E"><gtr:id>D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E</gtr:id><gtr:name>City, University of London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A32E0CF1-72B8-47D2-A614-D74456F65DFD"><gtr:id>A32E0CF1-72B8-47D2-A614-D74456F65DFD</gtr:id><gtr:name>Positive Voices</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2B4890EC-5704-4F99-AE13-CC1371378CBB"><gtr:id>2B4890EC-5704-4F99-AE13-CC1371378CBB</gtr:id><gtr:name>Copenhagen University Hospital</gtr:name><gtr:address><gtr:line1>Kettegaard Alle 30</gtr:line1><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A2A453F-81B2-4B90-B942-A83268D4F47F"><gtr:id>0A2A453F-81B2-4B90-B942-A83268D4F47F</gtr:id><gtr:name>CheckpointLX</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB"><gtr:id>F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB</gtr:id><gtr:name>University of Paris Diderot (Paris 7)</gtr:name><gtr:address><gtr:line1>6th European PCRD</gtr:line1><gtr:line2>13 rue Pierre et Marie Curie</gtr:line2><gtr:postCode>F-75205</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421AD70F-9A6E-48CE-9C42-6C508F1FBAD8"><gtr:id>421AD70F-9A6E-48CE-9C42-6C508F1FBAD8</gtr:id><gtr:name>Eastern Virginia Medical School (EVMS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7E3C0045-B615-48B0-B761-74896FEED7ED"><gtr:id>7E3C0045-B615-48B0-B761-74896FEED7ED</gtr:id><gtr:firstName>Sheena</gtr:firstName><gtr:surname>McCormack</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122861322"><gtr:id>CC567E92-EB53-416C-87A8-9A9199E01B40</gtr:id><gtr:title>Prevention Programme - Microbicides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122861322</gtr:grantReference><gtr:abstractText>The focus of this programme is to develop female controlled methods to prevent HIV which are safe, effective and affordable. |This large project brings together several experts in a partnership across Europe and Africa in the microbicide field. A microbicide is a product used vaginally to prevent infection by HIV or other sexually transmitted infections (STIs). A particular microbicide (PRO 2000/5) was selected after being tested in the laboratory and tested for safety. Once found to be safe, studies were undertaken by African partners to prepare for a large trial. This multi-centre Phase III trial began in October 2005 and recruitment closed in August 2008. 9385 women were enrolled from the following sub-Saharan African sites, in South Africa (Johannesburg, Soweto and Orange Farm, Durban, Tongaat, Verulam Isipingo, Africa Centre), Tanzania (Mwanza), Uganda (Masaka), Zambia (Mazabuka). The last visit took place in September 2009. Unfortunately, we demonstrated conclusively that PRO 2000/5 vaginal gel did not prevent HIV infection. This was disappointing as promising results were reported earlier in 2009 in an independent smaller trial, which we now know were due to chance.|We are now concentrating on the more potent anti-retroviral microbicides (anti-retrovirals are specific for HIV and used for treatment).</gtr:abstractText><gtr:technicalSummary>The focus of this programme is to develop female controlled methods to prevent HIV which are safe, effective and affordable. |In the absence of an effective vaccine to prevent the spread of HIV-infection and the continuing HIV pandemic, which is particularly devastating in sub-Saharan Africa there is an urgent need to develop alternative methods of prevention. Women in sub-Saharan Africa are particularly vulnerable being unable in most instances to negotiate the use of condoms with their partners. |A central objective is the development and clinical assessment of candidate microbicides for the prevention of vaginally acquired HIV infection. The CTU is jointly co-ordinating the multi-disciplinary Microbicides Development Programme with Imperial College at St Marys Hospital, London.||The initial work focused on testing the safety of 2 candidate microbicides both in Europe (Antwerp and the UK) and in Africa (Uganda). In parallel to these trials, Feasibility studies were conducted in 6 African sites, to inform the design and size of a Phase 3 trial to assess two active products. A short Pilot study using placebo gel was conducted to validate the procedures planned for the main trial, and a final evaluation of the pre-clinical and clinical data was performed in August 2004 to select the product and concentration. A large Phase 3 trial of low and hig dose PRO 2000/5 vaginal gel began recruiting in 2005. CTU coordinated the development of the protocol, case record forms, database, monitoring, analyses and oversight (Trial Management Group, Trial Steering Committee and Data and Safety Monitoring Committee meetings).||Between October 2005 and August 2008 9385 women were enrolled from the following sub-Saharan African sites, in South Africa (Johannesburg, Soweto and Orange Farm, Durban, Tongaat, Verulam and Isipingo, Africa Centre), Tanzania (Mwanza), Uganda (Masaka), and Zambia (Mazabuka). Women were followed for at least 12 months (up to 24months in Uganda) and were asked to insert the gel pre-sex.||The trial assessed two doses of PRO2000/5 (2% and 0.5%) each in comparison with a placebo. In February 2008 the 2% gel was discontinued on the recommendation of the Independent Data Monitoring Committee as there was no more than a small chance of demonstrating benefit according to the original statistical plan.||Recruitment closed on the 15th of August 2008 and follow up will continue until August 2009. The study database was locked on the 1st November 2009 and the results were reviewed by the Senior Investigators, Trial Steering and Independent Data Monitoring Committees as well as two independent referees appointed by MRC prior to release of the result in December 2009. Unfortunately neither 0.5% nor 2% PRO 2000/5 reduced the incidence of HIV when compared to placebo gel.||The next scientific questions are focused around the more potent anti-retroviral microbicides, and MDP is preparing for the results of the CAPRISA 004 trial of tenofovir 1% vaginal gel which will report in July 2010. In anticipation of significant but moderate protection we are conducting a further pilot of daily placebo gel, the Top-Up study in 5 sub-Saharan countries: Uganda (Masaka), Tanzania (Mwanza), South Africa (Durban), and Zambia (Mazabuka) all of which participated in the Phase 3 trial, plus Mozambique (Maputo and Manhica) where they have successfully completed a Feasibility study. Three methods of collecting in the used applicators are being explored: daily, weekly and every 4 weeks at the clinic visits. Top-Up has been enrolling since June 2010 and is expected to report early 2011.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-12-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>7874932</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>An explanatory video has been produced with the aim of presenting the CHAARM project and its main goal. It explains what are microbicides and it shows why is important to develop alternative prevention methods, such as new combination of microbicides, for controlling the risk of HIV infection. Professor Sheena McCormack is featured in the video.</gtr:description><gtr:id>47E18BCE-0DCB-4A2E-ACEB-B5E8687A9EBA</gtr:id><gtr:impact>This film aimed to increase the profile of microbicides in Europe.</gtr:impact><gtr:outcomeId>545a6329a506f6.73173682</gtr:outcomeId><gtr:title>CHAARM video filming - 28th April 2014</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://chaarm.eu/content/newsroom</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>Professor Sheena McCormack: PROUD trial poem.
Launched at her Inaugural Professorship lecture, 25th Sept 2013. An artistic precis of the PROUD trial Informed Consent document.</gtr:description><gtr:id>02748A7A-301A-4E3F-836E-97DF4C3B5CB5</gtr:id><gtr:impact>661 YouTube hits as of 13th Nov 2014. 
A well publicised artistic interpretation of the PROUD trial to engage participants, public and the media.</gtr:impact><gtr:outcomeId>5464ca7c37fce9.60634182</gtr:outcomeId><gtr:title>PROUD trial poem, Prof. Sheena McCormack, Sept 2013</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://www.youtube.com/watch?v=hXxr01cgb_M</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>This was a documentary created by students and built around the personal experience of a close friend of theirs who had recently been diagnosed with HIV and who was considering participation in a research study.</gtr:description><gtr:id>39A9CC34-D616-4B05-A115-B1811A644289</gtr:id><gtr:impact>The film was well received at the graduation ceremony.</gtr:impact><gtr:outcomeId>545a62b8127631.50981537</gtr:outcomeId><gtr:title>Filming for Goldsmith's University BA Media student graduation documentary, 13th Jan. 2014</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>Professor Sheena McCormack featured in the video 'The Gold Standard: What are randomised controlled trials and why are they important?' available at http://www.ctu.mrc.ac.uk/resources/multimedia/</gtr:description><gtr:id>D6BC16F0-7095-4CBF-99FB-E5846C6CE236</gtr:id><gtr:impact>The film aimed to broaden understanding of clinical trials for lay and non-expert audiences.</gtr:impact><gtr:outcomeId>545a640f1cfa16.18724393</gtr:outcomeId><gtr:title>Contribution to video filming to feature on MRC CTU at UCL website</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://www.ctu.mrc.ac.uk/resources/multimedia/</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Paolo Hospital</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>5D7186E3-4E78-4ADF-969B-673FD307F753</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-12</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>School of Medicine and Medical Science</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>38EC9677-EBEC-42C8-A015-0E698C2796F1</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-4</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Positive Voices</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>09A30E7F-B1AC-41C8-A833-C779CE8996A3</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-11</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Paris Diderot University</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>CE3FEECA-1BB7-4374-88DB-4E7C45F25CFC</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-1</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>50C2357F-217B-40B8-91E5-28F8E95F1C0F</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-5</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Tropical Medicine Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>4B99680E-9496-48C3-9A27-D94A651D30F0</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-2</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Grant application for a clinical trial (PROUD trial)</gtr:description><gtr:id>5B9F9460-3B64-4605-98AD-543A917E2D34</gtr:id><gtr:impact>Grant application
Audit report
Development of mathematical model of transmission
Sigma panel report</gtr:impact><gtr:outcomeId>nrKcgsSx81Z-3</gtr:outcomeId><gtr:partnerContribution>Joint application to NIHR/HTA for a large HIV prevention trial.
Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics. Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics. Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics.Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics.</gtr:partnerContribution><gtr:piContribution>Coordination. Primary responsibility for application and drafting trial documents (protocol, information sheet, informed consent etc)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>311528CA-518F-4267-9C47-9FFB33862F95</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-6</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moscow Regional AIDS Centre</gtr:collaboratingOrganisation><gtr:country>Russian Federation</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>D0E67292-83B8-4AA2-B942-29C1E1CCA0F2</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-15</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Praxis Jessen2 and Kollegen</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>8499FBB8-A75A-4EA7-A443-F21463FC385C</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-10</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portuguese Group of Activists Treatments for HIV/AIDS Pedro Santos (GAT)</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>049CC575-02A4-4315-BFD3-BFA65D5B7505</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-7</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Copenhagen University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>17360FE9-522D-4D96-B0E3-02EDC643634D</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-9</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>BE07E05E-5E26-4463-BCED-57F4D9A15A32</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-6</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>52757B24-3DE4-4777-B890-8F8C6F4794E7</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-1</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>51A14871-E1A3-46FD-8911-1F674F91038F</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-3</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Infectious Diseases (Lazzaro Spallanzani IRCCS)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Epidemiology</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>C748183B-3B92-458C-AA0B-49740E01BBC5</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-3</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Grant application for a clinical trial (PROUD trial)</gtr:description><gtr:id>71C542AC-B864-446D-9CEC-1890916F3965</gtr:id><gtr:impact>Grant application
Audit report
Development of mathematical model of transmission
Sigma panel report</gtr:impact><gtr:outcomeId>nrKcgsSx81Z-4</gtr:outcomeId><gtr:partnerContribution>Joint application to NIHR/HTA for a large HIV prevention trial.
Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics. Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics. Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics.Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics.</gtr:partnerContribution><gtr:piContribution>Coordination. Primary responsibility for application and drafting trial documents (protocol, information sheet, informed consent etc)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. James's Hospital, Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>4AB8E6FA-5ED9-45E0-B18C-C78C7513B81F</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-8</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>City, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>9A6A507A-C29A-4853-BAD7-E561DF9EE47A</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-2</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CheckpointLX</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>06147AD3-0C83-44BE-820D-F68EE33F4F90</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-14</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>C539E4BC-2DCF-4F16-BA62-AA257F3F19C7</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-4</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Virginia Medical School (EVMS)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Contraception Research and Development (CONRAD)</gtr:department><gtr:description>Microbicides Development Programme (MDP) and CONRAD tenofovir project</gtr:description><gtr:id>84FE3182-48FF-44E5-B188-B403136B11C3</gtr:id><gtr:impact>Full funding application to EDCTP 15th March 2016, but not funded.</gtr:impact><gtr:outcomeId>54623574017df4.16347308-1</gtr:outcomeId><gtr:partnerContribution>CONRAD invited Professor Sheena McCormack to develop research proposals for CONRAD's Microbicide APS Objective 1 (MAPS1) which was successfully funded</gtr:partnerContribution><gtr:piContribution>Our research team developed research proposals to conduct a phase II clinical trial of tenofovir gel in either vaginal ring or tablet form, and an open-label wait listed design of tenofovir gel with Microbicides Development Programme partners in Uganda and Mozambique. 

Funding application currently being drafted for submission to EDCTP by 15th March 2016: 'A pragmatic, randomised open-label wait-listed trial to evaluate the effectiveness of tenofovir to reduce the risk of HIV acquisition among women involved in transactional and commercial sex in Mozambique, Rwanda, Tanzania and Uganda.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Grant application for a clinical trial (PROUD trial)</gtr:description><gtr:id>F8599E2E-28BA-4153-A607-55AB36ABFD5C</gtr:id><gtr:impact>Grant application
Audit report
Development of mathematical model of transmission
Sigma panel report</gtr:impact><gtr:outcomeId>nrKcgsSx81Z-1</gtr:outcomeId><gtr:partnerContribution>Joint application to NIHR/HTA for a large HIV prevention trial.
Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics. Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics. Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics.Joint application to NIHR/HTA for a large HIV prevention trial. Supported by a range of activities across these partnerships: modelling, behavioural data collection, health economics, audit of HIV testing and behavioural interventions in clinics.</gtr:partnerContribution><gtr:piContribution>Coordination. Primary responsibility for application and drafting trial documents (protocol, information sheet, informed consent etc)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nye Pluss</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>B89095B5-F2AA-4D71-8766-5F0FC97C31AE</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-13</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Hospital Clinic of Barcelona</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>E673FA7D-F03F-4F73-8C01-CFCEAF90E5CF</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-16</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>48852628-EDA8-4E12-B859-BB9A5C9BB940</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-7</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GGD Amsterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>D0D94383-E403-4A3B-AD6C-390ABD93DC44</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-5</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited speaker at international conference, Oct 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0743FA7F-7D0D-4C2A-88AA-06E01516FF61</gtr:id><gtr:impact>Several hundred delegates attended the plenary session 'ART for prevention - roll it out?' at the European AIDS Clinical Society 2013 held in Belgium.

This provided an opportunity to raise awareness of PrEP in Europe. The only two countries with ongoing PrEP activitieis in Europe are France and the UK, and yet this intervention is highly relevant to the European epidemic which is focused in MSM and drug users.</gtr:impact><gtr:outcomeId>DTNtF1DuSmf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.eacsociety.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article in Gay Star News: UK to be offered pill that reduces HIV risk by up to 90%; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DB549FF7-8982-435C-9115-7F89E324028B</gtr:id><gtr:impact>Article featured some quotations from interviews with other journalists published in other journals.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>546400df945884.58686755</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.gaystarnews.com/article/uk-be-offered-pill-reduces-hiv-risk-90171014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - QX Magazine article: The Young People's Discussion Of HIV: A Review, published 1st Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D425340-B3A2-49AF-B89A-1BE84D04756E</gtr:id><gtr:impact>? The Young People's Discussion of HIV was assembled by QX as part of Soho sexual health clinic 56 Dean Street's Gay Men's Wellbeing Programme, sponsored by the Monument Trust. Lots of discussion, this article arose and a further article with QX pending for Dec 2014.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463eb706438f3.49980512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.qxmagazine.com/feature/the-young-peoples-discussion-of-hiv/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EDCTP HIV Stakeholders meeting, Sep 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>92240045-35F8-4AD0-9A09-2F15C67296B6</gtr:id><gtr:impact>There were about 100 delegates from Africa, Europe and the US that attended this meeting. The majority were senior and influential academics or from normative agencies.

I am uniquely privileged to be working in microbicides, vaccines and PrEP to reduce the risk of HIV, and across the spectrum of product development from Phase I through to implementation. This was a excellent opportunity to provide a perspective balanced by the breadth and depth of my clinical trial experience.</gtr:impact><gtr:outcomeId>LGPvQqb1UEn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.edctp.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD Community Engagement (CEG) meeting, 3rd Sept 2014.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E87A7CA5-A362-48A0-8042-EA636EF1AE98</gtr:id><gtr:impact>Agreed plans for the HTA application, PPI payment policy and participant reimbursement policy

Informed the submission of the HTA trial funding application</gtr:impact><gtr:outcomeId>545bac34df7bf6.69298437</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation by Gus Cairns to UK CAB: Who accesses PrEP? PROUD study baseline data analysis, 24th October 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D0D52527-02ED-41D9-995A-E9385C7F997B</gtr:id><gtr:impact>UK-CAB 52: Sexual health and HIV

Well received presentation

-</gtr:impact><gtr:outcomeId>5458cfa004d858.28135275</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.ukcab.net/wp-content/uploads/2014/10/PROUD-study-pilot-baseline-data.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD Participant Involvement Meeting (3rd): 9th Sept 2014 in person meeting and 11th Sept 2014 teleconference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2F8C721C-4C38-4A5B-9D2D-FF40AAA82AAE</gtr:id><gtr:impact>Date: 9th September 2014 (in-person) and 11th September 2014 (teleconference)
Location: MRC CTU (Aviation House) and by phone 
Facilitator: Mitzy Gafos 
Topic: Study design and data collection tools for a larger PROUD trial.
Attendees: 12 study participants (10 in-person and 2 on teleconference) with representation from Barts, Dean St, John Hunter, Mortimer Marker, St Mary's, and St Thomas's.
Discussed 6 questions in 3 breakout groups

Informed study thinking on the following topics: PrEP access post follow-up, clinical trial design, clinical trial study visits, clinical trial data collection methods, PPI payment, and participant reimbursement policy</gtr:impact><gtr:outcomeId>5452763b8d9752.10350231</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk/patient_and_public_involvement.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for Independent article: NHS to offer tablet which can reduce HIV risk by 90%; published 16th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3FBB2843-7B84-46C6-AE3F-F6AA58ED2041</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463f9d4b5d418.52786427</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.independent.co.uk/life-style/health-and-families/health-news/nhs-to-offer-tablet-which-can-reduce-hiv-risk-by-90-9799965.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with The Lancet for article: Uptake of PrEP for HIV slow among MSM, published 1st Feb 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>284D7FCB-DD27-480E-BE67-14F434F5014C</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54639c84750a02.78783147</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60137-9/fulltext</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with Mancunian Matters for article: 'The anti-HIV drug cure-all? Gay Manchester men offered pill to prevent infection in ground-breaking trial', published 15th Oct 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>09867F49-05FE-47DF-8972-A5FFF806F854</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>546399072b23f9.86886940</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.mancunianmatters.co.uk/content/151059198-anti-hiv-drug-cure-all-gay-manchester-men-offered-pill-prevent-infection-ground</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article AIDSMap/NAM: PROUD UK PrEP study completes enrolment - first data give participants' background and risk factors, published 9th April 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95F317BB-22EF-4B56-8804-1167B83F90A4</gtr:id><gtr:impact>Article by PROUD Community Engagement Group member/TSC Co-Chair.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463e5b6bedc24.17010734</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.aidsmap.com/page/2845218/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos presented: 'An update on Pre-Exposure Prophylaxis (PrEP)' to the BASHH North Thames Branch meeting, London, 20th November 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>04450650-B391-4D23-AC9A-B81A9233BC70</gtr:id><gtr:impact>Raised awareness and interest in the PROUD study

-</gtr:impact><gtr:outcomeId>545ab6cab07118.94934233</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD Community Engagement Group (CEG) meeting, 14th Oct. 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>13E1CD90-0093-47D2-975C-6C823537CE8F</gtr:id><gtr:impact>Updated CEG members of the IDMC recommendation in confidence and developed a dissemination strategy for the discontinuation of the deferred study arm

Supportive statements from CEG members once IDMC recommendation released on 16th October 2014</gtr:impact><gtr:outcomeId>545abde2f09682.68062497</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article on www.BHIVA.com: Second European PrEP study is closed early due to high effectiveness; published 29th Oct. 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31877C84-A73D-4A32-9684-EB55103AB424</gtr:id><gtr:impact>Article provided by Gus Cairns, PROUD Trial Steering Committee co-Chair.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>546403ba5060a5.44206653</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bhiva.org/News.aspx?NewsID=f83f28a9-80f6-415f-8039-c5d35dbe483c</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article in International Business Times: HIV 'Breakthrough' Drug Reduces Risk of Infection by up to 92%: What is Truvada?; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>255BDB73-1A18-40AE-95D0-88B2CF97DEC6</gtr:id><gtr:impact>Article written.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fecd64a6a7.65680216</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.ibtimes.co.uk/hiv-aids-breakthrough-drug-reduces-risk-infection-by-92-what-truvada-1470559</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinic Seminar, April 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FCB7C2B5-3A8F-4878-8990-10286EE8B30F</gtr:id><gtr:impact>40 healthcare professionals from 56 Dean Street clinic attended this talk on PrEP and PROUD.

Healthcare professionals seeing gay men at risk of HIV have referred these men to the PROUD study team.</gtr:impact><gtr:outcomeId>p9ejPewgu9R</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> AVAC Tenofovir gel working group (TGWG)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D7554FF0-C8CF-4293-8AF3-934886E0B1E8</gtr:id><gtr:impact>AVAC TGWG host regular teleconferences with advocates and scientists. I provide regular updates to the international group of approximately 100 members internatinally on teleconferences.



Produced a document summarising 'frequently asked questions' about tenofovir gel.</gtr:impact><gtr:outcomeId>dKF1VL58n9h</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral presentation by Richard Stack: PrEP and PROUD, SSHA Annual Conference 21st Sept 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>90297C1A-688B-494D-8241-2DC19808FAAE</gtr:id><gtr:impact>Invited presentation prepared by MRC and given by a PROUD researcher to 80 delegates at the SSHA conference.
Conference: SSHA Annual Conference
21st September 2013, London
Title: PREP and PROUD

Increased awareness among Sexual Health Advisers about PROUD. Disseminated healthcare workers survey at the conference.</gtr:impact><gtr:outcomeId>AiWrQb4JT1D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National AIDS Manual/AIDS Vaccine Advocacy Coalition Webinar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>559C9547-B680-458A-9B4C-D70398A6498E</gtr:id><gtr:impact>80 people joined the webinar, and the slides and audio are available on the NAM/AVAC websites.

Positive feedback from the organisers.</gtr:impact><gtr:outcomeId>DK1PburP8Zd</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.avac.org/ht/display/EventDetails/i/49928/TPL/MatDetails/pid/351</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Advocates Guide to the R4P Conference - webinar, 6th Nov. 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E9C293E5-864B-4A86-95A9-7D7B866135E0</gtr:id><gtr:impact>The webinar was organised to provide feedback on R4P Conference, the first international HIV prevention conference to bring vaccines, microbicides and PREP together. I was asked to speak specifically on the take home messages regarding prevention for gay men in Europe following the iPerGay and PROUD announcements. These two trials reported early due to interim analyses demonstrating that PrEP was highly effective in reducing the risk of HIV in an event driven regimen (iPerGay) and taking acccount of any change in risk behaviours (PROUD). 
There was also feedback regarding a number of Good Participatory Practice presentations after which I was able to make the point that Community Engagement has always been at the heart of preparing for large HIV prevention trials.

I was emailed after the webinar by researchers and Communtiy Advocates who agreed with the points I had made.</gtr:impact><gtr:outcomeId>545a6522d816a2.96754633</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Catherine Montgomery presented 'Events, Looks, Data: Friction and Lubrication' at a meeting: New Methodologies for Interdisciplinarity in HIV and Related Health Fields, 25th June 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0F942E7C-97D0-4E4B-A523-3CFE9A822FA3</gtr:id><gtr:impact>Dr. Catherine Montgomery presented: 'Events, Looks, Data: Friction and Lubrication in Clinical Trials', referring to MDP301 trial data in her presentation.

Attended by 35 people

-</gtr:impact><gtr:outcomeId>5459014c574b74.49550069</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media: Interview to contribution to article: The Truvada Wars; BMJ 24th June 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E7D66F25-B414-4231-9553-B591EAFA2126</gtr:id><gtr:impact>Prof. Sheena McCormack interviewed by Julia Belluz 16th April 2014 for an article that Julia went on to have published in the BMJ. 
Article title: The Truvada Wars (published 24th June 2014).

BMJ2014;348 doi:http://dx.doi.org/10.1136/bmj.g38111 (Published 24 June 2014)
Cite this as: BMJ 2014; 348:g3811


Increased awareness</gtr:impact><gtr:outcomeId>5457c3613b5a29.88657216</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.bmj.com/content/348/bmj.g3811</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with The Daily Mail for article: 'Pressure grows on NHS to make new HIV wonder drug available for those at risk', published 17th May 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C10D7A06-B13F-43B7-A8E5-409E419EB3A9</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463e8a0572052.41988193</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dailymail.co.uk/news/article-2631219/Call-HIV-pill-gay-men-risk-infection-available-NHS.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for Dirtyboyz for article July 2014 issue (pp. 54-55)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F6756FBA-9E6C-49AD-B6F0-02CFFED22B75</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463e9930e9b50.22493859</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article on www.HIVandHepatitis.com: High Effectiveness Seen in English PrEP Trial, All Will Be Offered Truvada; published 17th Oct. 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2ADFE5D0-BED9-4A01-AAEB-1B2F1EC7668D</gtr:id><gtr:impact>Article produced in collaboration with AIDSmap.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>546401c2f16764.71576240</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.hivandhepatitis.com/hiv-prevention/hiv-prep/4890-high-effectiveness-seen-in-english-prep-trial-all-will-be-offered-truvada</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gus Cairns, PROUD Community Engagement Group member and PROUD TSC Co-Chair provided a radio interview to www.voiceofrussia.com/uk on 10th Feb. 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9C7D36C8-EAAA-4D19-8A70-D12CB156862C</gtr:id><gtr:impact>Shared information about PrEP

Increased awareness of PrEP</gtr:impact><gtr:outcomeId>5458c022441f52.79180567</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World AIDS Day talk, St. Anne's Church, Soho, 1st Dec. 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8249F55B-273B-43E5-886D-56FBC125DD73</gtr:id><gtr:impact>This was a moving occasion as people reminisced about the 30 years of the AIDS epidemic. I was asked to talk about what it had meant for me as a clinician and researcher. I recalled how my role started as palliative care for young, vibrant individuals who were destined to die an untimely death, how we scarcely dared believe in the efficacy of triple therapy, and how exciting it was now to have new ways in which to use these same drugs in HIV negative individuals to prevent HIV. In particular I recalled the courage, humour and integrity demonstrated by patients I had had the privilege to look after in the early years.

Several members of the audience were appreciative of the perspective I had been able to provide. Two students from Goldsmith's University approached me and asked me to take part in a documentary film that they were making.</gtr:impact><gtr:outcomeId>54567b58577d41.17169452</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with trial participant writing an article for The Gay UK: So Why Are So Many Gay Men Opposed To PrEP? published 16th Oct 2014.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EC0F335A-BB77-4BE5-B2E6-2C5D978EE003</gtr:id><gtr:impact>Interview with PROUD trial participant who wanted to write an article.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>546461b5c0cce0.43507297</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thegayuk.com/magazine/4574334751/So-Why-Are-So-Many-Gay-Men-Opposed-To-PrEP/8625632</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos presented on &quot;PrEP- is the time right?&quot; Update on the PROUD study to the Wessex BASHH Regional Clinical Network Group Meeting 19-11-2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2B49C465-43A8-45E5-8BD3-D38663D801FA</gtr:id><gtr:impact>The presentation generated a discussion about PrEP roll out in the UK - providers wanted more information about cost effectiveness, toxicity, resistance and targeting of PrEP in the NHS (15 doctors and health advisers present)

The presentation will be shared around the group</gtr:impact><gtr:outcomeId>546f0997440640.40645074</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article in The Guardian: Can this HIV drug help to end 30 years of blighted lives? 29th Sept 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A1A23EA3-45DC-4EA5-98A3-D72B653D02C1</gtr:id><gtr:impact>Article: Terrence Higgins Trust quoted (Cary James).

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>546464dd8a4523.03832175</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.theguardian.com/commentisfree/2014/sep/29/new-hiv-drug-truvada-gay-men-us-nhs</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with i-Base for article: The little blue pill that can stop HIV: UK PROUD study, article published 22nd Nov 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78C57237-696A-42AC-9EEF-4B8932DA483B</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54639b7d96bd99.82258339</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://i-base.info/the-little-blue-pill-that-can-stop-hiv/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Sue Fleck presented at a Careers Conference, University of East London, 2nd April 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>17ECB074-E6E2-4BD3-A279-9A64D8B8B698</gtr:id><gtr:impact>Well attended presentation ~100 attendees. Lots of questions and an attentive audience.
Presentation title: Working for Research Funding Organisations, Job Opportunities for Science Graduates at the Medical Research Council (MRC) Clinical Trials Unit (CTU) @ University College London (UCL)


Requests for further information.</gtr:impact><gtr:outcomeId>5458c3d37a8251.18975860</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos led an Adherence Workshop, 29th Sept 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4929385E-0E34-414C-BE9E-3F89E3505A26</gtr:id><gtr:impact>We identified the need to engage a broader audience and are working towards a national conference

We shared experiences, circulated data collection tools and posted a report of the meeting</gtr:impact><gtr:outcomeId>545cd76d1520a0.26329017</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - AIDSMap article: 'The road to PrEP: trials, regulation and roll-out', 25th June 2012</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86B2DEE6-1EEA-44A4-B167-AFE69D49E65A</gtr:id><gtr:impact>Interview with article author

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>546396626023b8.32223352</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.aidsmap.com/The-road-to-PrEP-trials-regulation-and-rollout/page/2403757/</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with The Times for article: Coming soon: the daily pill that can protect against HIV; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2D097A08-85B6-448B-966A-FBE043BB5BC6</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fb3072d951.70131820</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thetimes.co.uk/tto/health/news/article4239078.ece</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - PROUD trial poem on YouTube, Prof. Sheena McCormack, 25th Sept 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5445B9FE-AB74-4F91-9FE7-B6BAD6BED72D</gtr:id><gtr:impact>A well documented and viewed artistic interpretation of the PROUD trial Informed Consent sheet.
Very well received.

661 YouTube hits as of 13th Nov 2014 and well publicised on social media. Increase in requests for information and participation in the PROUD trial.</gtr:impact><gtr:outcomeId>5464cbc1f13556.71064911</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.youtube.com/watch?v=hXxr01cgb_M</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South Yorkshire HIV Clinical Network meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E60BADA6-9D59-46A2-9D7B-CE418217C5FD</gtr:id><gtr:impact>About 60 people from various disciplines attended this meeting at which I was asked to talk on 'Will PrEP reduce HIV in the UK?'

There was a lively debate and very helpful exchange regarding the challenges faced in engaging gay men in South Yorkshire.</gtr:impact><gtr:outcomeId>NN7RZguUo3y</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'The Young People's Panel Discussion on HIV', Twentieth Century Fox Screening Rooms, Soho, 24th Sept. 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>99F222E8-182B-42D5-926A-CF8B2452F5DD</gtr:id><gtr:impact>It was an event flagged in QX, funded by Monument Trust, and organised through a collaboration between 56 Dean Street and QX which focused on young people and HIV prevention. There was a film, a brief update on PrEP and PROUD and a panel discussion which was then opened up to the floor - all in the 20th Century Fox building in Soho Square. 

Presentations from Dr Alan McOwan and Professor Sheena McCormack of 56 Dean Street on PrEP and the PROUD study respectively.

The panel discussion was illuminating, highlighting how important stigma still was for a generation that has become sexually active during a period when HIV was a treatable condition. There was a lively discussion following the panel and an opportunity to set the record straight with respect to the reasons for chosing PrEP and the benefits. There were several PROUD participants in the room who spoke eloquently about the alleviation from anxiety and the guilt as taking PrEP is a way to be responsible about the health of self and partner at times when a condom is not used.</gtr:impact><gtr:outcomeId>54567c7c25d521.17112407</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Rectal Microbicides: the bottom line on HIV Prevention',  17th Sept. 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8B85A475-4578-494D-AC32-2B80DD830A18</gtr:id><gtr:impact>Coordinated by the PROUD team, hosted by THT, London, and faciliated by Jim Pickett, Director of Prevention Advocacy and Gay Men's Health at the AIDS Foundation of Chicago.
Generated discussion about future HIV prevention options - especially PrEP and rectal microbicides

Lots of questions/discussion to be taken on board for future rectal microbicide study design/acceptability.
Report in draft for circulation</gtr:impact><gtr:outcomeId>545abcc9912720.00562381</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos presented: 'An update on Pre-Exposure Prophylaxis (PrEP)' Burrell Street, St. Thomas' at Burrell Street clinic, St. Thomas', London 6th November 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2334455B-5F30-4CCC-A732-7D4A7A939BAE</gtr:id><gtr:impact>Shared information about PROUD and the eligibility criteria and enrollment targets

Motivated for increased referral of eligible participants from health care providers</gtr:impact><gtr:outcomeId>545ab64d494f44.14034914</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Robin Shattock presented at the All-Party Parliamentary Group meeting focussed on AIDS, TB and Malaria, 25th Feb 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C280CD8-64F6-4D15-8729-68EBB44472FF</gtr:id><gtr:impact>Professor Robin Shattock, Faculty of Medicine, Department of Medicine, Imperial College. Chairman of Mucosal infection and immunity and member of IAVI's Scientific Advisory Committee. Prof. Shattock addressed resistance to ARVs, therapeutic vaccines, the role of PrEP and the development of preventive vaccines.



Prof. Robin Shattock presented the challenges with resistance to ARVs which led on to discussions about why additional prevention options including microbicides and vaccines are needed. Slides on the UK HIV Resistance Database were presented also. Greater understanding gained by the APPG.</gtr:impact><gtr:outcomeId>5458c25eee5e30.02705724</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.lstmliverpool.ac.uk/events/february-2014/25-feb-all-party-parliamentary-group-on-malaria-and-neglected-tropical-diseases-meeting</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media: Boyz article titled 'PrEP Up' 27 November 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BA346CE-C623-4DBA-AC4E-0BC405BA3F42</gtr:id><gtr:impact>The article increased awareness of PrEP

No impact to date</gtr:impact><gtr:outcomeId>547340dd320982.18486745</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.joomag.com/magazine/boyz-magazine-1213/0609721001417000705?short</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'PEP and PrEP: the science behind the strategies', NHIVNA Study Day, 6th March 2013, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0F3160C7-8367-44B0-8ECE-2B31A1D5AA0B</gtr:id><gtr:impact>The talk resulted in questions and discussion which provided helpful insights into the way that clinics work around the country.

The most result was the realisation that clinical nurse specialists lacked confidence to talk to their HIV positive patients about treatment as prevention. The reason for this was consultant ambivalence regarding the evidence. There is no ambivalence about the evidence and I hope that the nurses who attended left with that key message, empowered to have discussions with their patients in future.</gtr:impact><gtr:outcomeId>54561dd36e7a83.09728072</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article in The Guardian: 'Honestly, it's a revolution. It's so great taking control', published 24th Sept 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D4E1B0F7-7471-4773-916A-CCA017635757</gtr:id><gtr:impact>Article on Truvada with comments from PROUD trial participant.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>54646369f2cec5.31967001</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.theguardian.com/society/2014/sep/24/truvada-hiv-aids-you-tell-us</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos on behalf of the PROUD Study presented: 'PPI: Involving Participants in the PPI strategy of the PROUD study' at a Participant Engagement workshop, MRC CTU at UCL, 17th June 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>38212D3B-CB16-4952-B3A0-5A6312542C40</gtr:id><gtr:impact>Presented experiences of involving study participants in PPI activities

Increased discussion about the role of study participants in PPI</gtr:impact><gtr:outcomeId>545abb18eb1cf5.57511563</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for QX Magazine for article: PrEP Yourself; published 22nd Oct 2014.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D5190AC2-8002-45E5-BA23-BC340D66E6D3</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>546402bc562dc4.22821618</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.qxmagazine.com/feature/prep-yourself/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media: DW.DE Radio: Truvada Trials (27th November 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C28CA0C1-D6AD-4B65-9EA9-C4A1FBD38DEB</gtr:id><gtr:impact>Increased awareness of PrEP - PROUD and IPERGAY

No impact yet</gtr:impact><gtr:outcomeId>5476f4373f4643.13584685</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dw.de/program/s-1452-9798</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD  Community Engagement Group (CEG) meeting, 9th April 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>17A9E24F-45BE-42EC-B2B3-CCF5D329EBCF</gtr:id><gtr:impact>Discussed progress on enrollment, participant involvement meetings and end of study plans

Shared information including recent BHIVA presentation slides</gtr:impact><gtr:outcomeId>545ab805d69038.06231451</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'HIV Ways of Knowing symposium', Homerton University Hospital, 1st October 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F0FDF0EE-6CA8-4337-8609-B20FB2BEC96E</gtr:id><gtr:impact>Dr. Iain Reeves mentioned the PROUD trial within a session on &amp;quot;Treatment an intervention research&amp;quot;
Attended by Liz Brodnicki, PROUD Trial Manager

-</gtr:impact><gtr:outcomeId>5457bc8db2e6b1.11724392</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with The Independent for article: 'Make new HIV protection pill available on the NHS, say sexual health campaigners', published 16th May 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CD44A762-A2F0-4DE9-B043-1DC1136039C0</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463e6b12d2603.99538386</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.independent.co.uk/life-style/health-and-families/health-news/make-new-hiv-protection-pill-available-on-the-nhs-say-sexual-health-campaigners-9387332.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK CAB Educational Talk (Oct 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60F1FEAB-1FEE-4E6E-B533-D4256426F46B</gtr:id><gtr:impact>The talk was entitled &amp;quot;Drug development in relation to PrEP and the PROUD study.&amp;quot; It was an hour long educational talk for around 20 members of UK CAB representing patient groups. The session encouraged questions throughout and the final 15 minutes took the opportunity to describe the PROUD study, in particular the design. Participants were engaged and we discussed the difficulties a deferred design may present. (David Dolling)

Feedback from the meeting was positive and the session was highly rated.</gtr:impact><gtr:outcomeId>P7HrS8mYqxK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with Baseline for article PrEP: Next Step?, published 10th July 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>47780098-5CBB-4246-BC04-2F85A2821D4B</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>5463982a2fa5d1.86544726</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.baseline-hiv.co.uk/hiv-articles/2013/7/10/prep-next-step</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sex, Drugs and MSM</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4D222FFF-2E90-4E6C-8EC7-AA620F91B42E</gtr:id><gtr:impact>About 100 participants from academic insitutions, healthcare and community organisations attended this workshop in Birmingham (Lakeside Centre) which was organised by the BASHH Special Interest Group for MSM. My talks was entitled 'PrEP and PEP'.

Stimulated discussion regarding universal access to PrEP in the UK.</gtr:impact><gtr:outcomeId>ZN4XwUW4fr6</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.bashh.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>An update on the PROUD pilot study, Dr. Monica Desai, presented at BASHH OGM, London, 14th April 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>779B9AC2-F278-4449-84D9-7E92E579EF1C</gtr:id><gtr:impact>Well received talk, lots of questions.

Increase in requests for information.</gtr:impact><gtr:outcomeId>54568e97321ba2.82108468</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article in AIDSmap/NAM: European CDC cautious about PrEP; published 18th July 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1E696CDB-BDE8-48EB-BB1F-5DB7BB9F8FAC</gtr:id><gtr:impact>Article written by PROUD Trial Steering Committee co-Chair/Community Engagement Group member.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>54646040d86a59.77031731</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.aidsmap.com/European-CDC-cautious-about-PrEP/page/2891977/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos attendance at the AVAC Communications Working Groups meeting on 30th April and 1st May, New York</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2122E577-6E68-408F-BF56-8B65E9216F45</gtr:id><gtr:impact>Discuss communications needs of HIV prevention

Inform communication priorities for coming year</gtr:impact><gtr:outcomeId>5458fba05cf185.47421455</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD Community Engagement Meeting, Jun 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4AB22818-C6BB-43B3-A551-DF19C3BCDC14</gtr:id><gtr:impact>14th June 2013 - We invited a range of stakeholders from community organisations working with gay men, representatives from the gay press and gay dating agencies such as Grindr. We facilitated discussions about The workshop focused on discussing three key issues: Lack of knowledge/awareness of PrEP; risk awareness; and Improving awareness about PrEP

Approximately 16 people attended the workshop. The outcomes were summarised in a meeting report for internal use. Outcomes informed the subsequent messaging stategy and resulted in the development of a position statement on PrEP from the community groups who attended.</gtr:impact><gtr:outcomeId>WGPh2XEt4ML</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk/PDF/PrEP%20Community%20Statement.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos on behalf of the PROUD Study presented: 'An Update on the PROUD study of Pre-Exposure Prophylaxis (PrEP)', 5th June 2014, MRC Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>223121AB-BBF6-464C-A258-F43EDD977FE5</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>545ab9152a14a3.63930233</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National AIDS Manual/AVAC teleconference (9th May 2013)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4DE888C2-7C7E-4CD4-A998-6291E1BF7211</gtr:id><gtr:impact>Presented to a group of advocates, community members and researchers on &amp;quot;Social Science Research in PrEP&amp;quot;

Provided update on PROUD</gtr:impact><gtr:outcomeId>i8xHRNC6W5p</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LGF Community Workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>41476E2D-4BD9-424B-A254-9C9C6F4B9BD2</gtr:id><gtr:impact>The audience of about 50 was drawn mainly from community organisations, although there were commissioners of public health, healthcare professionals form clinics and other academics present. My talk was on PrEP and PROUD, the UK Pilot study of PrEP.

The talks were followed by working groups tasked with thinking of positive and negative aspects to PrEP. It was helpful to have this feedback to better understand what the challenges to roll-out are likely to be.</gtr:impact><gtr:outcomeId>grVdgf4k9js</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with Shmu radio, Aberdeen for World AIDS Day, 1st Dec 2013.</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>46FEA737-6391-487F-A936-0BA4069E69F2</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54567af85ccd31.86702719</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited to serve on Abstract Review Committee for BHIVA/BASSH 3rd joint conference (1-4th April 2014)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FEE9A3C4-1A3B-48B0-8796-309BA850E852</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>5458bdd41259c6.11527288</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.bashh.org/BASHH/Education/BASHH_Spring_Conference/BASHH_BHIVA_Conference_2014/BASHH/Education/BASHH_Spring_Conference/Joint_BASHH-BHIVA_Conference_2014.aspx?hkey=4f4a4db9-3f06-48ac-b02b-090c2664d646</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article in The Australian: Groundbreaking HIV pill developed in UK;published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0754A0B0-8F1B-42A8-96D1-038B46960A9A</gtr:id><gtr:impact>Article used quotations from interviews featured in other journals.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463ffe049b588.25924780</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.theaustralian.com.au/news/health-science/groundbreaking-hiv-pill-developed-in-uk/story-e6frg8y6-1227093514356?nk=db242896346ced37c5e5d4f9435cccb1</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited to Population Council select group dinner discussion on anti-LGBT legislation in Africa, London, 17th June 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>37F89AF2-CBFE-495F-AA2A-EA3991A1E3AE</gtr:id><gtr:impact>I was able to contribute very little except to emphasise that MRC was commited to equality and diversity but also to protecting the safety of employees, and that the anti-gay legislation created a tension in this regard as the safety of MRC employees could be jeopardised by speaking out against the government legislation.
The take home message for me is that it is the electorate that is ultimately responsible for encouraging politicians to pursue the anti-gay legislation and this speaks to a fundamental structural problem that requires further investigation to better understand the underlying factors before a comprehensive strategy can be proposed.

Good contacts with diverse organisations made, and a better understanding of the constraints under which HIV testing and STI screening are conducted in several countries in Africa.</gtr:impact><gtr:outcomeId>545621b179b871.74271910</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK PrEP eWorking Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>455CCB7F-F178-4759-8F55-7640D4F023BA</gtr:id><gtr:impact>Established eGroup
Held three conference calls and two meetings.
Continued dissemination of relevant clinical trial results with interpretation.


Constructive feedback on the concerns of the UK clinicians, community organisations, commissioners with respect to PrEP.
Input to design of proposed trial and dosing regimens.
Continued support.</gtr:impact><gtr:outcomeId>fRHLAHvZjmV</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article on HIV I-Base: Q and A on PrEP in the UK and changes to the HIV PROUD study; published 17th Oct. 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9221B07E-FAEE-4B36-91F0-56BF604C41F0</gtr:id><gtr:impact>Q&amp;amp;A article written.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fbfb251c92.61628820</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://i-base.info/qa-on-prep-in-the-uk-and-changes-to-the-hiv-proud-study/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview  with The Times for article: Trial of pill to prevent HIV could lead to rise in promiscuity, scientists admit; published 8th Feb 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>409AA6A6-64B6-4DA8-A9A3-386EEE244A96</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54639e1cce4403.48180941</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thetimes.co.uk/tto/health/news/article4000861.ece</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with QX Magazine for article: PREP: A new pill in the fight against HIV, published 4th July 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D347D3F-99F4-4A70-BDE9-A3FD619B3F08</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>5463973a22fe22.58632836</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.qxmagazine.com/feature/prep-a-new-pill-in-the-fight-against-hiv/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos presentation to UK-CAB (HIV Treatment Advocates Network): The Changing Landscape of Biomedical HIV Prevention Research, 25th April 2014, Birkbeck College, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1E527996-B646-434C-B0F6-90070D6F5DD6</gtr:id><gtr:impact>The meeting had 26 attendees, a third of whom came from outside London.
UK-CAB HIV treatment advocates network.
CAB 50: Looking backwards, moving forward

Feedback from Mitzy's session was rated excellent by over 50% and good by the rest. Audience feedback was that the presentation was good, engaging and that it enhanced their understanding.



Audience reported an improvement to their understanding following Mitzy's presentation</gtr:impact><gtr:outcomeId>5458cde1354ae0.46670399</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.ukcab.net/meetings/presentations/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Career pathways in Population Health</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>34E499AE-43B4-43F7-A67F-181C7C825E53</gtr:id><gtr:impact>60 students mainly from public health attended this careers day organised by the Royal Society of Medicine. I gave a talk entitled 'Big questions in clinical trials'.

Several students sought individual career advice following the talk.</gtr:impact><gtr:outcomeId>hJRs8bmFfv9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Satellite at AIDS 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F6DBAD8C-B04E-4F37-B35E-08B38A16A6DA</gtr:id><gtr:impact>Audience included media and community activitists. 
Expert panel after the presentation provided opportunity for feedback.
Also invited to speak to several journalists who subsequently included microbicides and PrEP in their articles.

Articles during and following the conference.
Constructive feedback helped inform the design of the study we plan in the UK</gtr:impact><gtr:outcomeId>EvMVFB31Fa1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with Baseline for article: Prep- Gets Real?, published 5th Nov 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2636B12D-FF17-460B-A402-4CF4EF41D37A</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54639a9b239b85.72092108</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.baseline-hiv.co.uk/hiv-articles/2013/11/5/prep-gets-real</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD PPI article: Involving 'seldom heard' groups in HIV research, INVOLVE website, November 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FD4BFFA7-F9F3-4497-8191-5785A8564F21</gtr:id><gtr:impact>Article posted on the INVOLVE website, November 2014 to raise awareness of PROUD PPI work.

To early to assess the impact of this article.</gtr:impact><gtr:outcomeId>5460ae373f15d8.36031108</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.invo.org.uk/involving-seldom-heard-groups-in-hiv-research/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for Daily Mail article: 'Wonder drug' which can reduce HIV risk by 92% could be offered on the NHS, published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>10AEB6BB-E280-4124-BD20-6291518D99AB</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463faa10d3c91.04919217</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dailymail.co.uk/health/article-2796900/wonder-drug-reduce-hiv-risk-92-offered-nhs-landmark-trial-sped-up.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MMCI, PrEP and Vax Comms call, 4th Feb. 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78DF2315-BF3A-46C7-A0A1-25275BC19A09</gtr:id><gtr:impact>Mitzy Gafos joined call for update on injectables

-</gtr:impact><gtr:outcomeId>54563f053cc7e9.67127640</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AVAC PReP communications group annual meeting (April 2013)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>39151E8C-3CBA-44D6-81D7-FB1E57791CB3</gtr:id><gtr:impact>The AVAC annual meeting was held from 2nd to 4th April 2013 in New York, USA, to discuss PrEP, microbicides and vaccine media and communications work. The workshop was attended by advocates, researchers, and communications experts.

The meeting was an opportunity to share updates on the PROUD PrEP study and discuss future microbicide research.</gtr:impact><gtr:outcomeId>D7Epr4CPU9S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement of PROUD trial participants / sharing of information through trial the PROUD trial website www.proud.mrc.ac.uk</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8B92A833-BD52-4B9E-A5BA-07AAB8E8A211</gtr:id><gtr:impact>We engage with study participants, the media, academics and anyone interested in PrEP/HIV research through the study website which we regularly update.

Increase in enquiries relating to the PROUD trial.</gtr:impact><gtr:outcomeId>545cba27405fa4.79365559</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk</gtr:url><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article for AIDSMap/NAM: High effectiveness seen in English PrEP trial; published 16th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EC2AB56B-C876-4409-90E5-C84E05BD7514</gtr:id><gtr:impact>Article produced by Gus Cairns (co-chair of the PROUD Trial Steering Committee)/Community Engagement Group member.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463f914162b59.46665632</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.aidsmap.com/High-effectiveness-seen-in-English-PrEP-trial/page/2912952/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with Radio Russia for radio/online article: HIV prevention drug goes on trial in the UK, broadcast 10th Feb 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F4D4C377-C09D-48BF-B8E1-D5E25DB60ADE</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54639d7c19fda3.63425481</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://voiceofrussia.com/uk/news/2014_02_10/HIV-prevention-drug-goes-on-trial-in-the-UK-3396/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for BBC 5 Live for radio article: 14th July 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4FC3DE23-F0A9-44E6-BF4B-1CA4B0387CE7</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>54645f8c9b5118.29616838</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.scoop.it/t/mrc-news/?tag=HIV%2FAIDS</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article for Huffington Post: This New HIV Prevention Drug Could Soon Be Available To Those At Risk Of Infection On The NHS; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5D42B6CA-595F-402D-A028-E6675E05490D</gtr:id><gtr:impact>Article written (featured quotations previously mentioned in a Daily Mail article).

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fe19b1cfb2.00566835</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.huffingtonpost.co.uk/2014/10/17/drug-breakthrough-hiv-prevention_n_6002650.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>South East HIV Nurses Regional meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C6EBD304-6425-4924-B07C-4C3D29EAB69F</gtr:id><gtr:impact>I was invited to give a talk on PrEP to this regional meeting of nurses and health advisors. About 50 people attended and the talk stimulated lively discussion.

Several members of the audience told me that my talk had made them think again about the value of PrEP in the UK setting.</gtr:impact><gtr:outcomeId>o7x8zaCDDY3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD study update presentation to the UK CAB (MG)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F7233491-7877-4760-BB7C-1334AD1F5DB7</gtr:id><gtr:impact>My presentation was one of four presentations about PrEP. The sessions generated discussion about future access to PrEP. A number of the CAB members are also members of the Clinical Reference Group (CRG) who will be involved with the review of PrEP in the future.

The group identified a series of questions that they intended to present to Gilead including the cost of Truvada and licensing of Truvada at the EMA.</gtr:impact><gtr:outcomeId>54c64387c32ee0.45924940</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ukcab.net/meetings/next-meeting/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos presented An Update on PROUD to the European AIDS Treatment Group (EATG) Webinar 2: PrEP on 24-11-2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2F91EA92-FCAC-4FFF-9C96-C355D3E0D6B0</gtr:id><gtr:impact>Initiated discussion about PrEP in Europe

Linkage with European advocates</gtr:impact><gtr:outcomeId>546f0ad54184f4.19919937</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.avac.org/event/eatg-webinar-2-pre-exposure-prophylaxis</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos oral presentation on behalf of the PROUD Study: 'The changing language of HIV prevention', Barts hospital, 18th June 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C1763594-6D91-4C47-BF9E-BCDAD24E326D</gtr:id><gtr:impact>Increased awareness among healthcare providers and Q&amp;amp;A session

Increased interest in the PROUD study</gtr:impact><gtr:outcomeId>5460e722e6d236.98321684</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos presented at the MRC CTU at UCL General Staff meeting, 1st July 2014 - update on the PROUD pilot study</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2569D18B-B19E-4088-993D-3D1657C7D7D2</gtr:id><gtr:impact>Increased awareness of PROUD study and generated discussed

Increased awareness among CTU members</gtr:impact><gtr:outcomeId>545abc2f5797b1.62046042</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD presentation, Dean Street clinic, 11th June 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A4827355-7F0B-4038-8F0D-2B8600E627C2</gtr:id><gtr:impact>Prof. Sheena McCormack presented to the Health Advisors at Dean Street clinic. Health Advisors are the frontline staff that speak to gay men most at risk of catching HIV, and those that have just found out they have HIV infection. I was invited to provide an update on the PROUD study.

Increased knowledge amongst staff, and improved my understanding of access to behavioural interventions facilitating future referrals for participants on the PROUD study.</gtr:impact><gtr:outcomeId>5456214a2e7d04.95957392</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Helen Rees webinar for AVAC on HC and HIV during which she referenced MDP data,10th March 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5D48FB1B-4592-47D1-9CD3-CDD3557A9D02</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>5458c320ea2632.15957229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article on www.RT.com: HIV drug cutting transition risk 90% may be offered on NHS; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C04690EC-5174-462B-8B58-D94FE2B55B78</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fd0f848545.08307994</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://rt.com/uk/196816-drug-reduce-hiv-nhs/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD presentation/update to London (NW) CLRN Infectious Diseases and Microbiology Specialty Group Open Meeting, 4th Dec. 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0B7D3F8C-243A-4912-A1D7-B1905BDE0264</gtr:id><gtr:impact>Well attended.
Very helpful update on the anticipated changes to the CLRN especially the interactions with NHS Trusts.

Informed the group about the PROUD trial and developments in PrEP, to promote better understanding amongst healthcare professionals.</gtr:impact><gtr:outcomeId>545616d8c8ec79.73747551</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AVAC PrEP communications working group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11E1E6E3-D07D-42F3-BF6E-1AF5E8A8533A</gtr:id><gtr:impact>AVAC PrEP communications group host regular teleconferences with advocates, scientists and funders. I provide regular updates to the international group of approximately 60 members internatinally on teleconferences.


Discussed the PROUD pilot study planned in the UK.</gtr:impact><gtr:outcomeId>cSnj7iwy8Sn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Use of Social Media for recruitment to HIV prevention research projects: Cuthivac 01 trial</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F39461EE-7E85-43FA-BE5D-037AB403E303</gtr:id><gtr:impact>Use of Twitter and Facebook for information sharing and to stimulate recruitment to the Cuthivac 01 vaccine study.

An increase in enquiries. Both studies now fully enrolled.</gtr:impact><gtr:outcomeId>5460e684b39833.17652083</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited to speak at PrEP and PEPSE panel, BHIVA Autumn Conference, London, 9-10th Oct. 2014</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>35589EDC-E9B9-415F-BDA4-F5C8D895FBA7</gtr:id><gtr:impact>BHIVA Interactive Clinical Conundrums: PrEP and PEPSE, 10th October 2014
Panel: Professor Sheena McCormack, MRC CTU at UCL and Dr Andy Williams, Barts Health NHS Trust, London


-</gtr:impact><gtr:outcomeId>54563081524de6.97739332</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Inaugural lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0D412D95-E8C3-4A6B-88FC-4DD12A60C183</gtr:id><gtr:impact>About 200 people from a range of disciplines and including the general public and school children attended and it was an opportunity to raise awareness of the ongoing HIV epidemic, the dramatic advances in biomedical interventions for the prevention of HIV and the importance of behaviour.

The lecture was videoed and posted on YouTube and tweeted.</gtr:impact><gtr:outcomeId>CCbPswDJyWf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article for HIV I-Base: UK PROUD study to provide PrEP earlier than expected: planned follow-up in this HIV prevention study to continue for two years; article published 16th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>99942BF9-6B33-4B7A-89C7-9150E0501F01</gtr:id><gtr:impact>Article written by independent member of the PROUD IDMC (Simon Collins).

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463f84df31202.29985967</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://i-base.info/uk-proud-study-to-provide-prep-earlier-than-expected/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr. Mitzy Gafos presented: 'User perspectives, acceptability and adherence', WHO meeting, 25th March 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11CD19D2-FE72-4FDB-8C5E-C7AC58D6D8C5</gtr:id><gtr:impact>The presentation was part of a 'Stakeholder Consultation on Priority Implementation Research to Inform Development of WHO Normative Guidance on Topical Pre-Exposure Prophylaxis'; input contributed to shaping a policy document.

Raised discussion regarding the role of self reported adherence data and the need to consider tools, such as BMQ, to predict adherence</gtr:impact><gtr:outcomeId>545ab760097958.49779499</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with Under the Rainbow on Pure 107.8FM (LGBT community radio station, Stockport), 24th October 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8226641D-4339-4C90-80A0-886C9B7BB206</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>546399b73e2a13.54894850</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD Participant Involvement Meeting (1st), 12th Nov. 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6718E84D-E2E6-44DD-B458-66522E7FB600</gtr:id><gtr:impact>Attendees: 8 study participants - only one or two from out of London
Call notes: Six of the eight participants joined by phone and two joined on-line.
Topic: What about after the PROUD pilot study? A discussion about what the next steps should be in terms of finding the most appropriate ways of making PrEP available in the UK
Presentation given entitled 'Future Options for PROUD'
Presentation and meeting notes published on the PROUD website www.proud.mrc.ac.uk

Discussed reasons for slow recruitment that helped inform recruitment strategy
Discussed next steps for PrEP in the UK which helped inform future planning</gtr:impact><gtr:outcomeId>5452741903bbe1.68488360</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk/patient_and_public_involvement.aspx</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD Participant Involvement Meeting (2nd), 19th March 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3D37AB2E-663C-44F5-A885-6FF3979A2363</gtr:id><gtr:impact>Topic: Future HIV prevention research priorities: a discussion about research priorities in the event that PROUD demonstrates benefits of PrEP in the UK 
Future HIV prevention research priorities presentation
17 study participants with representation from Dean St (8), John Hunter (3), Barts (2), St Thomas's (2), MMC (1), Homerton (1)
Meeting presentation and notes published on http://www.proud.mrc.ac.uk/patient_and_public_involvement.aspx

Discussed acceptability of clinical trial designs (especially use of placebo and deferred arm) and research priorities which informed strategic thinking about next clinical research priorities for HIV prevention research</gtr:impact><gtr:outcomeId>545274cf396eb5.28861342</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk/pdf/Report%20on%20Second%20Participant%20Involvement%20Meeting_19March2014.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4851440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROUD trial: Medical Research Council Clinical Trials Unit Core funds, Gilead Sciences Inc., Health Protection Agency (HPA) / Public Health England (PHE)</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>-</gtr:fundingRef><gtr:id>01ED61AE-C5F7-42AE-B8C2-7E60DABEEF23</gtr:id><gtr:outcomeId>QFWxXwhU9az</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European PrEP Group</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>9892E5D5-9429-4701-A2C7-1851DEA26A6D</gtr:id><gtr:impact>This group was initiated and is coordinated by Sheena McCormack to provide a forum for exchange of knowledge and sharing tools (surveys, data collection forms, protocols etc) in order to accelerate research into pre-exposure prophylaxis (PrEP) in Europe. Although there have been multiple clinical trials assessing PrEP, none of these were conducted in European populations prior to 2012 when iPerGay and PROUD launched in France and the UK.</gtr:impact><gtr:outcomeId>546392894a5c53.30289613</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IAPAC Consensus Statement, 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>99563F8F-8376-44A4-9607-CFBC0C6D6E74</gtr:id><gtr:outcomeId>CiryYKYQUZC</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PROUD presentation, Dean Street clinic, 11th June 2014</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>DB115B3B-00A5-48E0-89E6-467C30F232D6</gtr:id><gtr:impact>Increased awareness of PrEP and facilitated referral of gay men at risk of acquiring HIV for behavioural interventions.</gtr:impact><gtr:outcomeId>546385c26cd8c0.08887748</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Entry in the EDCTP Annual Report 2013 (published June 2014)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7D60B1AF-FD74-49CE-8EF3-03572A249A20</gtr:id><gtr:impact>The MDP301 project which EDCTP co-funded was chosen as an example of good practice. EDCTP funding allowed microbicides to be introduced into Mozambique for the first time, with training of clinicians and researchers largely undertaken by the team from the University of Witswatersrand in Johannesburg.</gtr:impact><gtr:outcomeId>5464a1e9db3395.86076221</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.edctp.org/annualreport2013</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Europrise Steering Committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>1F25F537-2FA4-4BD8-AA36-701A42453959</gtr:id><gtr:outcomeId>AhdQK7jo7SR</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>'PEP and PrEP: the science behind the strategies', NHIVNA Study Day, 6th March 2013, London</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>CCBDBA78-DC05-47EB-951B-A178ABF3880D</gtr:id><gtr:impact>Empowered clinical nurse specialists to talk to their HIV positive patients about treatment as prevention.</gtr:impact><gtr:outcomeId>5463875c3ebd94.14381249</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PrEP policy sub-group of national HIV clinical reference group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>169D0739-8710-46AB-BCA7-865C052D7A07</gtr:id><gtr:outcomeId>545a340fe2c145.81292765</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Select Committee chaired by Lord Fowler</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6C26554E-D09E-4A3B-A0DD-A40BA9C828EE</gtr:id><gtr:impact>Following this consultation home testing for HIV was became legal (April 2014)</gtr:impact><gtr:outcomeId>AERENfstqK2</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CMO Seminar on future public health policy for HIV research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FB4D89EE-30C2-413D-825B-0AC9BFA5676F</gtr:id><gtr:impact>As a result of the seminar the CMO wrote to all GPs advising them to test patients presenting with glandular fever symptoms for HIV. The legalisation of self-testing was also raised and subsequently the CMO announced that the law would be changed from April 2014.</gtr:impact><gtr:outcomeId>nm2cFyDZQkt</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Stakeholder Consultation on Priority Implementation Research to Inform Development of WHO Normative Guidance on Topical Pre-Exposure Prophylaxis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1EDC4701-F5E3-4184-8C11-24B7229382FE</gtr:id><gtr:outcomeId>54630ef1337c65.66229590</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.conrad.org/news-meetings-35.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Good Participatory Practice Guidelines: case studies</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>644808B7-FFC5-413A-B698-F6E918E020F4</gtr:id><gtr:impact>Shared to research staff as lessons to improve implementation of GPP</gtr:impact><gtr:outcomeId>FZdEeAwnmam</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.avac.org/implementation-tools</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Consultation on Standards of Care in HIV prevention trials</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>C3163398-31AA-4BE6-801A-B8F690D2008E</gtr:id><gtr:outcomeId>hXiihyQweUw</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>PROUD is designed to address an unique question regarding Truvada-PrEP, namely the effectiveness when people know they are on a drug that reduces HIV, as this may lead people to increase their risk and as a consequence expose themselves to more HIV and sexually transmitted infections (STI). Gay men are randomised to have access to daily oral Truvada at enrolment or after one year of follow-up, and all participants have access to the standard prevention package throughout.

Truvada as PrEP has been licensed as PrEP in the USA and this is a pilot study.

Funding provided through: MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences. 

544 study participants currently in active follow up.

The PROUD trial reported at the Conference for Retroviruses and Opportunistic Infections (CROI), February 2015 http://www.croiwebcasts.org/console/player/25539?mediaType=audio&amp;amp;</gtr:description><gtr:id>48584539-5DB4-4FC4-86DD-D89282685D78</gtr:id><gtr:impact>PROUD was a game changer for PrEP for two reasons. Firstly Truvada was more effective at preventing HIV in this open-label pilot phase than in previously reported placebo-controlled trials, and secondly the trial schedule mirrored routine practice with quarterly visits, whereas previous trials had followed a monthly schedule. The study was conducted in men who have sex with men (MSM) attending sexual health clinics in England. When PROUD announced the decision to offer PrEP to those whose access was deferred, IPERGAY asked their Data Monitoring Committee to advise them what to do in their placebo-controlled trial which was also being conducted in MSM, in France. It transpired that Truvada was equally effective when MSM were advised to take drug before and after sex. This caused tremendous excitement when the results were presented back to back at an international conference, and the excitement sparked enthusiasm across Europe.

In November 2015 the French regulatory authority approved the use of Truvada as PrEP on a named patient basis, and the French Minister of Health announced at the end of the same month that the costs of the drug would be fully reimbursed by the social security system. NHS England is about to issue a Commissioning Policy for public consultation.</gtr:impact><gtr:outcomeId>NdjYsZQiRyt</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Pre-exposure prophylaxis for HIV infection (PROUD trial)</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:url>http://www.proud.mrc.ac.uk</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The database was developed by the MRC CTU at UCL team to allow study participants to remotely record sexual and adherence behaviour on daily diaries and monthly questionnaires.</gtr:description><gtr:id>133C591F-C018-4DF6-8B09-E8D32D285E95</gtr:id><gtr:impact>The database has allowed real time data collection directly from study participants</gtr:impact><gtr:outcomeId>546236826aa658.92598906</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PROUD participant database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>The PROUD database was developed by the MRC CTU at UCL data team and allows data to be entered remotely from each of the 13 PROUD study clinics as well as directly at CTU.</gtr:description><gtr:id>B0EE5D30-E48B-45C1-AE90-D075AED6D61A</gtr:id><gtr:impact>The database has facilitated real time data entry at each PROUD study clinic and supported data management.</gtr:impact><gtr:outcomeId>54623620ee2d10.83681517</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PROUD study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The PROUD study Social Science Advisory Group developed the PROUD one-to-one (or in-depth interview) guide in order to interview participants enrolled in the PROUD pilot study</gtr:description><gtr:id>6EC3B6E6-8E48-4D43-8720-E0EFE5779611</gtr:id><gtr:impact>The one-to-one guide will be used throughout the pilot study to collect qualitative data on study acceptability, PrEP experiences, PrEP adherence and the impact of PrEP on sexual behaviour</gtr:impact><gtr:outcomeId>54623c9474ebf7.51506714</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PROUD study One-to-one Interview guide</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://www.proud.mrc.ac.uk/social_science_study_component.aspx</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The PROUD study protocol was developed by the MRC CTU at UCL team. The PROUD pilot study protocol defines the following study: PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men.
The protocol includes participant information sheets, informed consent forms and CRFs.</gtr:description><gtr:id>7ED37304-B47B-4C3F-BB7D-5FEF6E45883A</gtr:id><gtr:impact>The PROUD pilot study has been conducted under protocol v1.1, 1.2.1, and now 1.3.</gtr:impact><gtr:outcomeId>54623b1511dea5.86233726</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PROUD pilot study protocol</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:url>http://www.proud.mrc.ac.uk/study_protocol.aspx</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The MRC CTU at UCL data team developed a mobile application to allow study participants to remotely access the PROUD participant database from mobile smart devices.</gtr:description><gtr:id>C5019EBF-7881-4557-9914-90D2B467F955</gtr:id><gtr:impact>The application was developed in response to participants requests for remote access to the database from smart devices and therefore was a direct response to study participants requests.</gtr:impact><gtr:outcomeId>546237755004a9.69035677</gtr:outcomeId><gtr:title>PROUD participant database mobile application</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>57DA9E5F-E27B-4998-83D6-ACC86991FF6B</gtr:id><gtr:title>EDCTP Annual Report 2013</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd4b7d4599d04593792ac2562d0cc227"><gtr:id>fd4b7d4599d04593792ac2562d0cc227</gtr:id><gtr:otherNames>EDCTP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>-</gtr:isbn><gtr:outcomeId>545bb8d42a7988.91262683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>735F5BB7-B0F4-4F6F-A5AA-5C12EF7D53C1</gtr:id><gtr:title>The European preexposure prophylaxis revolution.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02c90827852f58069dfdf54947234e5"><gtr:id>f02c90827852f58069dfdf54947234e5</gtr:id><gtr:otherNames>Cairns G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>56b1d55147adb2.65006779</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D8DC6F2-2CB3-4CF5-9BF5-75712D9A315D</gtr:id><gtr:title>Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.</gtr:title><gtr:parentPublicationTitle>Developing world bioethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d1bb197cc904bb6e54a57f5b78db9ae"><gtr:id>2d1bb197cc904bb6e54a57f5b78db9ae</gtr:id><gtr:otherNames>Haire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-8731</gtr:issn><gtr:outcomeId>pm_14129_29_23725227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02B220E2-8DBC-43AF-B905-9CF7C0AB3E51</gtr:id><gtr:title>Shared responsibility for ensuring appropriate management of incidental findings: a case study from South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bd7edcd755cc6bc526fc8c795402462"><gtr:id>3bd7edcd755cc6bc526fc8c795402462</gtr:id><gtr:otherNames>Sookrajh Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>546254330df591.57583368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAC0ECFB-62B3-4687-9AB2-2A516A13C797</gtr:id><gtr:title>High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c466ae98f118459939cc3dd07cd9570d"><gtr:id>c466ae98f118459939cc3dd07cd9570d</gtr:id><gtr:otherNames>Naidoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>doi_55faa1aa16c947a0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>519F6F0D-7C81-4FD7-BCE1-1106768D923B</gtr:id><gtr:title>Microbicides from a regulatory perspective.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a70acb9aba00435f9a0a4de5461d1ec"><gtr:id>5a70acb9aba00435f9a0a4de5461d1ec</gtr:id><gtr:otherNames>Stone AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54625508515065.13576160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B900616-725E-4B5C-AB81-8BE99A2FB3C2</gtr:id><gtr:title>The last decade of microbicide clinical trials in Africa: from hypothesis to facts.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>Xz7eqRUVg3h</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>138F8782-89CB-4DDB-8032-75B8FA3F8492</gtr:id><gtr:title>HIV prevention research: taking stock and the way forward.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c148e9ffd758a895718cfd9de060388a"><gtr:id>c148e9ffd758a895718cfd9de060388a</gtr:id><gtr:otherNames>Hayes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>PoFtx7ohm73</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92DF38DD-1680-4964-B370-123F99F6B9B1</gtr:id><gtr:title>Oral presentation: Acute Hepatitis C in the PROUD pilot study.</gtr:title><gtr:parentPublicationTitle>-</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/468a1f21b90b1ce6a3f01ffd8194de8e"><gtr:id>468a1f21b90b1ce6a3f01ffd8194de8e</gtr:id><gtr:otherNames>Tiraboschi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b73a2cfb138.63210499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F438FD9B-5DCF-461B-97A4-340FE80463D8</gtr:id><gtr:title>Genital Tract Immunological Markers in Sub-Saharan African Women with Relevance to HIV Risk and Prevention</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6af6898898d5974a6f92bb656f8b213"><gtr:id>e6af6898898d5974a6f92bb656f8b213</gtr:id><gtr:otherNames>Kyongo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd22501e236.01391439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1676C161-CC4D-4DA0-B514-5FF34985BC4F</gtr:id><gtr:title>oral presentation: Science of PrEP</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545baa8e694c64.81515719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A29B22AB-294F-4966-913E-38AB39FB1A51</gtr:id><gtr:title>Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda.</gtr:title><gtr:parentPublicationTitle>Reproductive health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cf5c8e0ec541774232c6d8f0012bdce"><gtr:id>3cf5c8e0ec541774232c6d8f0012bdce</gtr:id><gtr:otherNames>Abaasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-4755</gtr:issn><gtr:outcomeId>58c668694c1729.72321987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FEA24C3-F4D1-4E37-AE88-9135EA99CF11</gtr:id><gtr:title>oral presentation: New strategies for prevention of HIV transmission</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545ba31c79a831.67598764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED185057-7337-4DBA-96B0-97DC7D529565</gtr:id><gtr:title>Hidden harms: women's narratives of intimate partner violence in a microbicide trial, South Africa.</gtr:title><gtr:parentPublicationTitle>Social science &amp; medicine (1982)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8abf5759c8e695e54167ce931c1417be"><gtr:id>8abf5759c8e695e54167ce931c1417be</gtr:id><gtr:otherNames>Stadler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-9536</gtr:issn><gtr:outcomeId>545cdfccc55fb0.72564065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB6D1905-AE17-4D7A-9B73-8B319C36FE4D</gtr:id><gtr:title>Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ee4e6d872e105b9c2c2dbaf4eaa52b"><gtr:id>69ee4e6d872e105b9c2c2dbaf4eaa52b</gtr:id><gtr:otherNames>Wand H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14129_29_20979651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CF35CA3-9E1B-408B-A364-81E6B7F7298B</gtr:id><gtr:title>Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa.</gtr:title><gtr:parentPublicationTitle>Journal of AIDS &amp; clinical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4699885e78f22938054f1dffd0990b"><gtr:id>3a4699885e78f22938054f1dffd0990b</gtr:id><gtr:otherNames>Ladep NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>FDSo6ewQneq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0419A6B6-E798-4009-9778-1E3D059292AB</gtr:id><gtr:title>Emergent HIV technology: urban Tanzanian women's narratives of medical research, microbicides and sexuality.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab512941caeb1aae2accf5cc6383f6ac"><gtr:id>ab512941caeb1aae2accf5cc6383f6ac</gtr:id><gtr:otherNames>Lees S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>doi_55faa1aa16c0991a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>986626EB-E618-4ACB-9DB2-2112C71FCC44</gtr:id><gtr:title>Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/440d093fa0202c6122edc3ba737de762"><gtr:id>440d093fa0202c6122edc3ba737de762</gtr:id><gtr:otherNames>Ssali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546256ac66e9e9.13074195</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2561603-9794-4D4E-86C4-26837E6428A0</gtr:id><gtr:title>Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c9a53574c8bab233260b7283f1a1653"><gtr:id>4c9a53574c8bab233260b7283f1a1653</gtr:id><gtr:otherNames>Lanham M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>546486b0c21482.78300623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE52F774-6374-491F-BF04-FB3405EC7DC8</gtr:id><gtr:title>Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a24619e8e97fd168eadaf7330b096d1"><gtr:id>7a24619e8e97fd168eadaf7330b096d1</gtr:id><gtr:otherNames>Torrone EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a9fbb5e696f06.54891249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A59E516-4D9D-4B3C-BFE5-6B4A7FFD79F9</gtr:id><gtr:title>China needs safe and effective microbicides for preventing sexual transmission of HIV.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ba550b2da219a38543bb38fa4b68ba"><gtr:id>d4ba550b2da219a38543bb38fa4b68ba</gtr:id><gtr:otherNames>Jiang S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>QC9kZiqtoTa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD267DBD-9085-46B4-837C-52BF5D44B40B</gtr:id><gtr:title>Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c9a53574c8bab233260b7283f1a1653"><gtr:id>4c9a53574c8bab233260b7283f1a1653</gtr:id><gtr:otherNames>Lanham M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>54648917a800b4.71271446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A09AE8E-F777-42F8-A021-627C0550F6A0</gtr:id><gtr:title>poster: The UK PROUD PrEP Pilot Study: a baseline analysis.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3217e8e9ffed562462fd4bb598c469b"><gtr:id>f3217e8e9ffed562462fd4bb598c469b</gtr:id><gtr:otherNames>Antonucci S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54623b5ac9c442.64917103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3294EB3B-8CEC-43D5-9206-07143095E622</gtr:id><gtr:title>How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>pm_14129_29_22971053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D20F745F-126A-43ED-AC7C-50BC97AA8619</gtr:id><gtr:title>'PROUD Study / PrEP( Pre-exposure prophylaxis for HIV) in the UK'</gtr:title><gtr:parentPublicationTitle>SSHA conference 2013</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b920e79b5706f95651d88ca123e075de"><gtr:id>b920e79b5706f95651d88ca123e075de</gtr:id><gtr:otherNames>Richard Stack (Senior Health Adviser - 56 Dean Street)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54647938f385a9.25233180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B7B8E46-4E8D-4C4A-8EAD-276E0B117157</gtr:id><gtr:title>Multipurpose prevention technologies for sexual and reproductive health: gaining momentum and promise.</gtr:title><gtr:parentPublicationTitle>Contraception</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/129e406f4c80dfd9cc551e170d20dbcc"><gtr:id>129e406f4c80dfd9cc551e170d20dbcc</gtr:id><gtr:otherNames>Holt BY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0010-7824</gtr:issn><gtr:outcomeId>Gm7HnXhLbyG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>187986F8-B143-4860-A8D0-98177872263C</gtr:id><gtr:title>Biomedical prevention: state of the science.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d39f838d6096e14629421fc2350d44"><gtr:id>a5d39f838d6096e14629421fc2350d44</gtr:id><gtr:otherNames>McCormack SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>544fb588a1a933.15031634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55F9FA1E-F201-488B-A31E-A05E26816AA4</gtr:id><gtr:title>Experiences in conducting multiple community-based HIV prevention trials among women in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>doi_55f983983681f4fa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A89FE1F3-F248-4CFF-B75B-6753B461F83F</gtr:id><gtr:title>Microbicides: where are we now and what next?</gtr:title><gtr:parentPublicationTitle>HIV Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>XKdvab6Sy42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C00A414-15DA-4741-B5BD-FB5E8E8009F9</gtr:id><gtr:title>Healthcare providers' knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56b1d551cee117.43618008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA5286D1-C379-422C-9619-C68A6BDE0624</gtr:id><gtr:title>Prevalence of Herpes Simplex Virus 2 (HSV-2) infection and associated risk factors in a cohort of HIV negative women in Durban, South Africa.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574366aefb678b01920bb269e942f55b"><gtr:id>574366aefb678b01920bb269e942f55b</gtr:id><gtr:otherNames>Daniels B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>5a2fd569515031.33031891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AD0FFDE-0B2A-4650-9CB0-510FF4E9128C</gtr:id><gtr:title>Statistical and methodological issues in microbicide trial design.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical obstetrics &amp; gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d16a0e2cac032025257ed2f44c93f19d"><gtr:id>d16a0e2cac032025257ed2f44c93f19d</gtr:id><gtr:otherNames>Crook AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1521-6934</gtr:issn><gtr:outcomeId>pm_14129_29_22305929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AF4E0E2-709B-426E-B0A9-B2EB4C15FD68</gtr:id><gtr:title>Oral presentation: Who accesses PrEP? An analysis of baseline data in the PROUD pilot.</gtr:title><gtr:parentPublicationTitle>-</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b5e05229791.03544838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2D04423-03B9-44AD-A4B9-2E227814FCDB</gtr:id><gtr:title>Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis.</gtr:title><gtr:parentPublicationTitle>Journal of the International Association of Providers of AIDS Care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f9f80fa02f967590b57ba33b56f6ef2"><gtr:id>3f9f80fa02f967590b57ba33b56f6ef2</gtr:id><gtr:otherNames>Mayer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2325-9574</gtr:issn><gtr:outcomeId>ckgSMcJF1P6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42F8B88F-3973-4F4E-8EF1-86E3A3D13234</gtr:id><gtr:title>oral presentation: Estimating the impact of pre-exposure prophylaxis for Men who have sex with Men (MSM) in England</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c5d11e5efe3a1efc71f66a225463c5"><gtr:id>a7c5d11e5efe3a1efc71f66a225463c5</gtr:id><gtr:otherNames>Nardone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b96486bfe42.47503061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCC70E2B-76AC-4537-BD8C-4D71A434CB48</gtr:id><gtr:title>The long-term impact of the MEMA kwa Vijana adolescent sexual and reproductive health intervention: effect of dose and time since intervention exposure.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5336c45429e06079cfa27cb14bdf976"><gtr:id>b5336c45429e06079cfa27cb14bdf976</gtr:id><gtr:otherNames>Doyle AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>AivMcePKTFu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00D4E529-72D6-414B-BF53-5914E4F844B6</gtr:id><gtr:title>poster: Healthcare providers' knowledge of, attitidues to and practice of pre-exposure prophylaxis for HIV</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545ba7d134c6d3.55128131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AD82858-FD09-4F56-B737-5EA3886AE5AB</gtr:id><gtr:title>The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>pm_14129_29_22362679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CE51079-9AB4-409C-9D8B-E4766D4FC596</gtr:id><gtr:title>Microbicide clinical trial adherence: insights for introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e32eed516dff4b5430c99619f7cdddf7"><gtr:id>e32eed516dff4b5430c99619f7cdddf7</gtr:id><gtr:otherNames>Woodsong C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14129_29_23561044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5949538D-E3E0-4275-B271-499B4C1B56B8</gtr:id><gtr:title>Regulatory issues in microbicide development</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f20eecb6910a162dc9976a5d5323f5a"><gtr:id>5f20eecb6910a162dc9976a5d5323f5a</gtr:id><gtr:otherNames>Stone, A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:isbn>978 92 4 159943 6</gtr:isbn><gtr:outcomeId>bhzUo246nvi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9B95C25-9BB3-4DC7-AE8C-1D879C673CC0</gtr:id><gtr:title>Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>pm_14129_29_23300336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48D4D1A6-7085-4600-9A5F-EDF30CFF0585</gtr:id><gtr:title>Microbicides: stopping HIV at the gate.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0faa7f8eec7970b9b2b3a1dd5c6ca15"><gtr:id>f0faa7f8eec7970b9b2b3a1dd5c6ca15</gtr:id><gtr:otherNames>Stone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>kve15QW3Ys3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B0E4AAA-CC6E-4D26-8500-A2E35249F0AA</gtr:id><gtr:title>'I heard about this study on the radio': using community radio to strengthen Good Participatory Practice in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5599b4ef58706984af5f9813297a7701"><gtr:id>5599b4ef58706984af5f9813297a7701</gtr:id><gtr:otherNames>Medeossi BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>545cdbd0cb8464.94826671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B62A4F39-E6D2-4C1E-9705-82D9916DD4AF</gtr:id><gtr:title>Communication About Microbicide Use Between Couples in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>54900c66767fb3.61564962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDD5EE05-3775-417F-A827-8F4A6486FEF5</gtr:id><gtr:title>Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e592a67027098903f7c40312ef17e6de"><gtr:id>e592a67027098903f7c40312ef17e6de</gtr:id><gtr:otherNames>Morrison CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56b1d5523c57c4.62705207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92CE01E3-79B1-4522-AA4C-372F3841D81C</gtr:id><gtr:title>poster: Healthcare providers' knowledge of, attitidues to and practice of pre-exposure prophylaxis for HIV</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b933a9b48b2.12338553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE69319C-BC7B-4A98-B846-E2C6E5E2AC1B</gtr:id><gtr:title>oral presentation: Sexual Behaviour Profile of Gay and Other Men Who Have Sex with Men (GMSM) Enrolled in the PROUD PrEP Open-Label Pilot Study in England (oral abstract session 07: Risk and Prevention for Men who Have Sex with Men)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b908b80a2b8.98377714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18AA6988-344A-4E66-8774-DF4314CF5A95</gtr:id><gtr:title>oral presentation: Engaging Male Partners in Women's Microbicide Use: Evidence from Clinical Trials and Implications for Future Research and Microbicide Introduction (oral abstract session 02 - Microbicides: Male Partner Engagement and Sexual Behaviors)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef7432fe95d5b4ff650dbadad93250a4"><gtr:id>ef7432fe95d5b4ff650dbadad93250a4</gtr:id><gtr:otherNames>Dayton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460b7de7ebff0.49179716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25B5F760-CA22-449F-92E5-3CE5349BD871</gtr:id><gtr:title>poster: Do patients adherent on PrEP exposed to HIV have seroconversion symptoms and falsely reactive HIV tests?</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6bdb91777a91f2fc38700e28a08ac25"><gtr:id>a6bdb91777a91f2fc38700e28a08ac25</gtr:id><gtr:otherNames>Roche M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545ba8d81cadb5.18815287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52EEAEAE-18A4-4DF9-890B-7A22C59223B8</gtr:id><gtr:title>Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56b1d5519d2325.22416090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>826BF66D-1841-4CB4-A597-482B97725918</gtr:id><gtr:title>AIDS. Turning the tide against HIV.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5f058242d4db29172cea243411fe1f0"><gtr:id>e5f058242d4db29172cea243411fe1f0</gtr:id><gtr:otherNames>Shattock RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>oKXpm5MCwPz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0605B775-4E76-4A3A-99B8-223F42944ACA</gtr:id><gtr:title>Welcome to the preexposure prophylaxis revolution.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18f91337e098e5467edbe78d0ef48eb3"><gtr:id>18f91337e098e5467edbe78d0ef48eb3</gtr:id><gtr:otherNames>Baeten J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>56b1d55118b456.66678220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>833B36B7-FB77-4FA6-99B0-AB12D53E33B8</gtr:id><gtr:title>Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4699885e78f22938054f1dffd0990b"><gtr:id>3a4699885e78f22938054f1dffd0990b</gtr:id><gtr:otherNames>Ladep NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>pm_14129_29_23538773</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122861322</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>